Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema

dc.contributor.authorObis, Javier
dc.contributor.authorArias Barquet, Lluís
dc.contributor.authorLorenzo, Daniel
dc.contributor.authorPadrón Pérez, Noel
dc.contributor.authorGarcía Bru, Pere
dc.contributor.authorCobos Martín, Estefanía
dc.contributor.authorMorwani, Rahul
dc.contributor.authorCaminal Mitjana, Josep Maria
dc.date.accessioned2021-11-18T09:41:03Z
dc.date.available2021-11-18T09:41:03Z
dc.date.issued2021-11-05
dc.date.updated2021-11-18T09:15:01Z
dc.description.abstractBackground: the purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). Methods: retrospective study of 33 eyes. Variables included best corrected visual acuity (BCVA; logMAR scale) and central retinal thickness (CRT) and central choroidal thickness (CCT) assessed with swept-source OCT. All patients were initially prescribed topical NSAIDs and reevaluated after 2 months. If improvement in BCVA or CRT was noted, topical NSAIDs were continued until resolution. If no improvement was observed at 2 months or subsequent visits, intravitreal dexamethasone implant was performed. Patients who refused intravitreal treatment were offered peribulbar triamcinolone. Results: after treatment with topical NSAIDs for a median of 2 months, BCVA increased significantly from 0.5 to 0.3 while CRT decreased significantly from 435 to 316 μm. PME resolved in 19 of the 33 eyes (57.6%). Of the 14 recalcitrant cases, 13 were treated with corticosteroids. Of these 13 cases, 9 (69.2%) resolved. BCVA increased non-significantly from 0.7 to 0.4. CRT and CCT decreased significantly from 492 to 317 μm and from 204 to 182 μm respectively. Conclusions: the overall success rate of the treatment algorithm was greater than 80%, a remarkable finding considering that no randomized study has yet been conducted to determine the optimal therapeutic protocol for PME. This is the first study to evaluate choroidal thickness in PME using SS-OCT, which could play a key role in its pathophysiology and provide useful information to improve the management of PME.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid34740334
dc.identifier.urihttps://hdl.handle.net/2445/181316
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12886-021-02132-w
dc.relation.ispartofBMC Ophthalmology, 2021, vol. 21, num. 1
dc.relation.urihttps://doi.org/10.1186/s12886-021-02132-w
dc.rightscc-by (c) Obis, Javier et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationEdema
dc.subject.classificationÚs terapèutic
dc.subject.classificationTomografia
dc.subject.otherEdema
dc.subject.otherTherapeutic use
dc.subject.otherTomography
dc.titleTopical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeinfo:eu-repo/semantics/article

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s12886-021-02132-w.pdf
Mida:
994.08 KB
Format:
Adobe Portable Document Format